CM/PHR/22/5686- NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies for the Treatment of Cancer
This is a contract result notice, not an open opportunity. Details from the official award data.
Proposed NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies for the Treatment of Cancer (Lots 1, 2, 3, 4 and 5)<br/>Tender Reference: CM/PHR/22/5686/01<br/> <br/>Period of framework agreement: 1 April 2024 to 31 March 2028 (covering regions East of England, London, North of England and South East).
What this notice demands of you
1 named, none in explicit obligation language. Each one is quoted from the notice.
CM/PHR/22/5686- NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies for the Treatment of Cancer
Matched against the notice text, so this is a floor — the tender pack will demand things the notice never mentions. “Says must” means the quoted sentence itself used obligation language; anything ambiguous is left as a mention.
Make the case to bid
Reveal who to approach at NHS England, and generate a go-to-market strategy from their news, accounts and people.
Free to start. Named contacts come from published notices; the strategy is generated from the buyer’s news, accounts and people.
- OCID
- ocds-h6vhtk-040faf
- Stage
- award · Awarded
- Source
- Find a Tender
- Buyer ref
- 010730-2024
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
Top suppliers & buyers in Medical Equipment & Pharmaceuticals
NHS England’s tender network